BRPI0618654A8 - variante de zimogênio/protease de fator x/fator xa, ácido nucléico, composição farmacêutica que os contém, vetor, bem como uso dos mesmos - Google Patents

variante de zimogênio/protease de fator x/fator xa, ácido nucléico, composição farmacêutica que os contém, vetor, bem como uso dos mesmos

Info

Publication number
BRPI0618654A8
BRPI0618654A8 BRPI0618654A BRPI0618654A BRPI0618654A8 BR PI0618654 A8 BRPI0618654 A8 BR PI0618654A8 BR PI0618654 A BRPI0618654 A BR PI0618654A BR PI0618654 A BRPI0618654 A BR PI0618654A BR PI0618654 A8 BRPI0618654 A8 BR PI0618654A8
Authority
BR
Brazil
Prior art keywords
factor
zymogen
vector
nucleic acid
pharmaceutical composition
Prior art date
Application number
BRPI0618654A
Other languages
English (en)
Inventor
M Camire Rodney
Original Assignee
Childrens Hospital Philadelphia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital Philadelphia filed Critical Childrens Hospital Philadelphia
Publication of BRPI0618654A2 publication Critical patent/BRPI0618654A2/pt
Publication of BRPI0618654A8 publication Critical patent/BRPI0618654A8/pt
Publication of BRPI0618654B1 publication Critical patent/BRPI0618654B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Abstract

composições e métodos para modular hemóstase. a presente invenção refere-se a variantes de fator xa e métodos de uso das mesmas sendo descritos.
BRPI0618654-8A 2005-11-15 2006-11-15 Variante de fator xa, composição farmacêutica que a contém, bem como uso dos mesmos BRPI0618654B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73668005P 2005-11-15 2005-11-15
US60/736,680 2005-11-15
PCT/US2006/060927 WO2007059513A2 (en) 2005-11-15 2006-11-15 Compositions and methods for modulating hemostasis

Publications (3)

Publication Number Publication Date
BRPI0618654A2 BRPI0618654A2 (pt) 2011-09-06
BRPI0618654A8 true BRPI0618654A8 (pt) 2019-01-15
BRPI0618654B1 BRPI0618654B1 (pt) 2021-10-19

Family

ID=38049397

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0618654-8A BRPI0618654B1 (pt) 2005-11-15 2006-11-15 Variante de fator xa, composição farmacêutica que a contém, bem como uso dos mesmos

Country Status (26)

Country Link
US (4) US8383386B2 (pt)
EP (4) EP2423224B1 (pt)
JP (4) JP5823088B2 (pt)
KR (4) KR101600158B1 (pt)
CN (1) CN101356192B (pt)
AU (1) AU2006315175B2 (pt)
BR (1) BRPI0618654B1 (pt)
CA (2) CA2629491C (pt)
CR (1) CR9956A (pt)
DK (1) DK1948690T3 (pt)
EC (1) ECSP088452A (pt)
ES (2) ES2496567T3 (pt)
GT (1) GT200800065A (pt)
HK (2) HK1128699A1 (pt)
IL (1) IL191310A (pt)
MX (3) MX2008006313A (pt)
MY (1) MY162181A (pt)
NO (3) NO345177B1 (pt)
NZ (1) NZ568108A (pt)
PL (1) PL1948690T3 (pt)
PT (1) PT1948690E (pt)
RU (2) RU2008123398A (pt)
SI (1) SI1948690T1 (pt)
SV (1) SV2008002906A (pt)
WO (1) WO2007059513A2 (pt)
ZA (1) ZA200804026B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824902A1 (en) * 2007-09-28 2021-05-26 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
CN102316893B (zh) 2008-11-14 2015-02-18 博尔托拉制药公司 因子Xa抑制剂的解毒剂及其与血液凝固剂组合使用的方法
EP2414517B1 (en) 2009-03-30 2016-09-21 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
JP6163304B2 (ja) 2009-07-15 2017-07-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子インヒビターの解毒剤の単位用量処方物およびその使用方法
KR20130136988A (ko) 2010-10-06 2013-12-13 메디뮨 리미티드 지혈 장애를 치료하기 위한 인자 ii 및 피브리노겐
CA2850603C (en) * 2011-09-30 2021-11-16 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
MX365612B (es) 2012-07-25 2019-06-07 Catalyst Biosciences Inc Polipeptidos de factor x modificados y usos de los mismos.
AU2014210830A1 (en) 2013-01-31 2015-07-16 Pfizer Inc. Compositions and methods for counteracting Factor Xa inhibition
FR3001729B1 (fr) * 2013-02-04 2015-03-06 Lab Francais Du Fractionnement Mutants du facteur x
WO2015044836A1 (en) * 2013-09-24 2015-04-02 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
WO2015066606A2 (en) * 2013-11-01 2015-05-07 The Children's Hospital Of Philadelphia Compositions and methods for increasing the half-life of factor xa
SI3096779T1 (sl) * 2014-01-24 2020-03-31 Pfizer Inc. Sestavki in postopki za zdravljenje intracerebralne krvavitve
BR112016027649A2 (pt) 2014-05-26 2017-08-15 Academisch Ziekenhuis Leiden Proteínas prohemostáticas para o tratamento de hemorragia
US10676731B2 (en) 2014-08-19 2020-06-09 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor IX function
CA3034566A1 (en) 2016-07-27 2018-02-01 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor ix function
WO2023118150A1 (en) 2021-12-22 2023-06-29 Royal College Of Surgeons In Ireland A conjugate for use in localising a molecule to the vascular endothelium.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093699A (en) 1987-07-09 2000-07-25 The University Of Manitoba Method for gene therapy involving suppression of an immune response
WO1994017810A1 (en) 1993-02-12 1994-08-18 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
WO1994023744A1 (en) 1993-04-16 1994-10-27 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
AU7676894A (en) 1993-08-27 1995-03-21 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Convection-enhanced drug delivery
AT401270B (de) 1994-09-26 1996-07-25 Immuno Ag Verfahren zur quantifizierung von genomischer dna
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
CA2188575A1 (en) 1995-02-28 1996-09-06 H. Kirk Hammond Gene transfer-mediated angiogenesis therapy
US6228646B1 (en) 1996-03-07 2001-05-08 The Regents Of The University Of California Helper-free, totally defective adenovirus for gene therapy
AT405517B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AT405516B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AT410216B (de) 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
WO2001070763A1 (en) * 2000-03-22 2001-09-27 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
FR2831170B1 (fr) * 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
FR2841904B1 (fr) * 2002-07-03 2004-08-20 Inst Nat Sante Rech Med Analogues de facteurs x clivables par la thrombine
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
CN104262479A (zh) * 2008-12-19 2015-01-07 国家健康与医学研究院 丝氨酸蛋白酶衍生物及其在凝血功能障碍的预防或治疗中的用途

Also Published As

Publication number Publication date
JP5823088B2 (ja) 2015-11-25
ECSP088452A (es) 2008-07-30
HK1128699A1 (en) 2009-11-06
AU2006315175B2 (en) 2013-02-07
ES2549929T3 (es) 2015-11-03
US9410137B2 (en) 2016-08-09
EP2431390A1 (en) 2012-03-21
US20140120155A1 (en) 2014-05-01
EP1948690A4 (en) 2009-06-17
PT1948690E (pt) 2014-09-08
EP2423224B1 (en) 2015-08-12
ES2496567T3 (es) 2014-09-19
KR101574042B1 (ko) 2015-12-03
SI1948690T1 (sl) 2014-09-30
US8383386B2 (en) 2013-02-26
EP2423224A1 (en) 2012-02-29
JP2009515559A (ja) 2009-04-16
MX2008006313A (es) 2008-11-06
NZ568108A (en) 2011-09-30
WO2007059513A3 (en) 2007-11-29
MX336958B (es) 2016-02-05
RU2011130932A (ru) 2013-01-27
CR9956A (es) 2008-08-21
CA2629491C (en) 2019-05-07
NO20082182L (no) 2008-07-30
BRPI0618654A2 (pt) 2011-09-06
SV2008002906A (es) 2008-10-22
IL191310A (en) 2015-06-30
MX337059B (es) 2016-02-09
ZA200804026B (en) 2009-10-28
CA2629491A1 (en) 2007-05-24
US20180251745A1 (en) 2018-09-06
KR101600158B1 (ko) 2016-03-08
US20090175931A1 (en) 2009-07-09
JP2016005464A (ja) 2016-01-14
RU2570547C2 (ru) 2015-12-10
EP1948690B1 (en) 2014-06-11
US9896676B2 (en) 2018-02-20
KR20080078664A (ko) 2008-08-27
NO20200671A1 (no) 2008-07-30
CA2971971A1 (en) 2007-05-24
NO345177B1 (no) 2020-10-26
RU2008123398A (ru) 2009-12-27
JP6571735B2 (ja) 2019-09-04
WO2007059513A2 (en) 2007-05-24
CN101356192B (zh) 2013-09-11
NO20200670A1 (no) 2008-07-30
JP2018033459A (ja) 2018-03-08
KR20160029135A (ko) 2016-03-14
KR20140005383A (ko) 2014-01-14
DK1948690T3 (da) 2014-09-01
PL1948690T3 (pl) 2014-11-28
US20160362673A1 (en) 2016-12-15
JP2014073127A (ja) 2014-04-24
KR20140115374A (ko) 2014-09-30
HK1165444A1 (zh) 2012-10-05
BRPI0618654B1 (pt) 2021-10-19
AU2006315175A1 (en) 2007-05-24
CN101356192A (zh) 2009-01-28
GT200800065A (es) 2008-11-03
EP2431389A1 (en) 2012-03-21
JP6236194B2 (ja) 2017-11-22
MY162181A (en) 2017-05-31
JP5957167B2 (ja) 2016-07-27
EP2431390B1 (en) 2015-08-12
EP1948690A2 (en) 2008-07-30
KR101827569B1 (ko) 2018-02-09

Similar Documents

Publication Publication Date Title
BRPI0618654A8 (pt) variante de zimogênio/protease de fator x/fator xa, ácido nucléico, composição farmacêutica que os contém, vetor, bem como uso dos mesmos
ECSP20027480A (es) Indolil alquil amino derivados sustituidos como nuevos inhibidores de la histona desacetilasa
CR11618A (es) Inhibidores macrocíclicos de serina proteasa
NO20075693L (no) Modulerende forbindelser av indolamin-2,3-dioksygenase og fremgangsmater for anvendelse av samme
BR112012019042A2 (pt) "inibidores de serina protease tipo tripsina, e sua preparação e uso".
CL2007001391A1 (es) Compuestos derivados de pirrolidinas sustituidas, inhibidores del factor xa y/o inhibidores sobre la serina proteasa; composicion farmaceutica que comprende a dichos compuestos; proedimiento para preparar la composicon farmaceutica; y uso de los compuestos preparar un medicamneto con un efecto antitrombotico
HN2007000267A (es) Compuestos de 4-metil piridopirimidinoma
BR112015007083A2 (pt) inibidores de histona demetilases
BR112015018508A2 (pt) moduladores de enzimas modificadoras de metila, suas composições e uso
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
CR10479A (es) Modulares bencimidazolicos de vr1
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
BR112013007862A2 (pt) ácidos nucleicos manipulados e métodos de uso dos mesmos.
NO20071077L (no) Fosfonatanaloger til HIV-inhibitorforbindelser
ES2572160T3 (es) Una nueva preparación farmacéutica para preeclampsia
ECSP10010246A (es) Inhibidores de beta-lactamasa
BRPI0520369A2 (pt) catalisador orgánico com compatibilidade intensificada de enzima
BRPI0408347B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
MX2009008925A (es) Compuestos de la formula (i) como inhibidores de proteasa de serina.
BR112013019643A2 (pt) inibidores de alk, uso e composição farmacêutica compreendendo os mesmos
HN2008000088A (es) Heterociclicos de 1,4-dihidropiridina- fusionada, procesos para preparar los mismos, su uso y las composiciones que los contienen.
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
ECSP088884A (es) Compuestos heterociclicos fusionados y su uso como moduladores de mglur5
ATE485261T1 (de) Salicylsäurederivate
BRPI0517035A (pt) novos compostos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2468 DE 24/04/2018 POR TER SIDO INDEVIDA.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/11/2006, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.